RMTG's ISSCA Regenerative Medicine Global Summit 2025 Concludes in Cancún with Full Attendance from 30+ Countries
Regenerative Medical Technologies Group (OTC:RMTG) announced that the ISSCA Regenerative Medicine Global Summit 2025 concluded Sept 12-13 at Secrets The Vine Cancún with full attendance from 30+ countries. The two-day program combined 14 keynote scientific presentations, five simultaneous hands-on certification workshops for 150 participants, exhibitor booths, and a soft opening tour of the new COFEPRIS-licensed CELLGENIC manufacturing laboratory. Revenue was generated via registration fees, certification programs, exhibitor booths, and product demonstrations while the event reinforced RMTG's integrated model of education, manufacturing, and distribution and highlighted recent geographic expansions.
Regenerative Medical Technologies Group (OTC:RMTG) ha annunciato che la ISSCA Regenerative Medicine Global Summit 2025 si è conclusa il 12-13 settembre presso Secrets The Vine Cancún con la partecipazione completa di oltre 30 paesi. Il programma di due giorni ha combinato 14 presentazioni scientifiche di rilievo, cinque laboratori pratici di certificazione simultanei per 150 partecipanti, stand espositivi e un tour di apertura soft del nuovo laboratorio di produzione CELLGENIC autorizzato da COFEPRIS. Le entrate sono state generate tramite quote di registrazione, programmi di certificazione, stand espositivi e dimostrazioni di prodotti, mentre l'evento ha rafforzato il modello integrato di RMTG tra istruzione, produzione e distribuzione e ha messo in evidenza le recenti espansioni geografiche.
Regenerative Medical Technologies Group (OTC:RMTG) anunció que la ISSCA Regenerative Medicine Global Summit 2025 concluyó los días 12 y 13 de septiembre en Secrets The Vine Cancún con asistencia total de más de 30 países. El programa de dos días combinó 14 ponencias científicas magistrales, cinco talleres prácticos de certificación simultáneos para 150 participantes, puestos de expositores y una visita de apertura suave al nuevo laboratorio de fabricación CELLGENIC autorizado por COFEPRIS. Los ingresos se generaron a través de tasas de registro, programas de certificación, puestos de expositores y demostraciones de productos, mientras el evento reforzaba el modelo integrado de RMTG de educación, manufactura y distribución y destacaba las recientes expansiones geográficas.
Regenerative Medical Technologies Group (OTC:RMTG)는 ISSCA 재생의학 글로벌 정상회담 2025가 9월 12-13일 Secrets The Vine Cancún에서 30개국 이상 전원이 참석한 채로 마무리되었다고 발표했습니다. 이틀 간의 프로그램은 14개의 기조 과학 발표, 150명을 대상으로 한 다섯 개의 동시 실습 인증 워크숍, 부스 전시 및 COFEPRIS의 허가를 받은 CELLGENIC 제조 연구소의 소프트 오프닝 투어를 포함했습니다. 등록비, 인증 프로그램, 부스 전시, 제품 시연을 통해 수익이 창출되었으며, 행사는 교육, 제조 및 유통의 통합 모델을 강화하고 최근의 지리적 확장을 강조했습니다.
Regenerative Medical Technologies Group (OTC:RMTG) a annoncé que le ISSCA Regenerative Medicine Global Summit 2025 s'est conclu les 12 et 13 septembre au Secrets The Vine Cancún avec une participation complète de plus de 30 pays. Le programme de deux jours a combiné 14 présentations scientifiques plénières, cinq ateliers pratiques de certification simultanés pour 150 participants, des stands d'exposants et une visite d'ouverture en douceur du nouveau laboratoire de fabrication CELLGENIC autorisé par COFEPRIS. Les revenus ont été générés par les frais d'inscription, les programmes de certification, les stands d'exposants et les démonstrations de produits, tandis que l'événement renforçait le modèle intégré de RMTG en matière d'éducation, de fabrication et de distribution et mettait en évidence les récentes extensions géographiques.
Regenerative Medical Technologies Group (OTC:RMTG) gab bekannt, dass der ISSCA Global Summit für regenerativmedizin 2025 am 12.–13. September im Secrets The Vine Cancún mit vollständiger Teilnahme aus über 30 Ländern zu Ende ging. Das zweitägige Programm kombinierte 14 Hauptvorträge wissenschaftlicher Natur, fünf gleichzeitige praktische Zertifizierungsworkshops für 150 Teilnehmer, Messestände und eine Soft-Opening-Tour des neuen COFEPRIS-lizenzierten CELLGENIC-Fertigungslabors. Die Einnahmen entstanden durch Registrierungsgebühren, Zertifizierungsprogramme, Messestände und Produktdemonstrationen, während die Veranstaltung das integrierte Modell von RMTG in Bildung, Herstellung und Vertrieb stärkte und die jüngsten geografischen Erweiterungen hervorhob.
Regenerative Medical Technologies Group (OTC:RMTG) أعلنت أن القمة العالمية للطب التجديدي ISSCA 2025 اختتمت في 12-13 سبتمبر في Secrets The Vine Cancún بحضور كامل من أكثر من 30 دولة. البرنامج الذي دام يومين جمع 14 عرضًا علميًا رئيسيًا، وخمسة ورش شهادة عملية متزامنة لـ 150 مشاركًا، وأكشاك عارضين وجولة افتتاحية ناعمة للمختبر التصنيعي CELLGENIC المرخّص من COFEPRIS. أُنتِجت الإيرادات من رسوم التسجيل وبرامج الشهادات وأكشاك العارضين وعروض المنتجات، بينما عزّز الحدث النموذج المتكامل لـ RMTG في التعليم، والتصنيع، والتوزيع وأبرز التوسعات الجغرافية الأخيرة.
Regenerative Medical Technologies Group (OTC:RMTG) 宣布，ISSCA 再生医学全球峰会 2025 于9月12-13日在 Secrets The Vine Cancún 结束，吸引来自超过30个国家的全体参会者。为期两天的项目包括14场关键科学主旨演讲、150名参与者的5场同步实操认证工作坊、展位以及经 COFEPRIS 许可的新 CELLGENIC 制造实验室的软启幕参观。收入来自注册费、认证项目、展位和产品演示，同时该活动强化了 RMTG 在教育、制造与分销的一体化模式，并突显了最近的地理扩张。
- None.
- None.
Two-Day Event Features Scientific Sessions, Hands-On Workshops, and Soft Opening of CELLGENIC Manufacturing Laboratory
LAS VEGAS, NEVADA / ACCESS Newswire / October 8, 2025 / Regenerative Medical Technologies Group, Inc. (OTC:RMTG), a global leader in regenerative medicine solutions, today announced the successful conclusion of the Regenerative Medicine Global Summit 2025, organized by the International Society for Stem Cell Application (ISSCA), the world's largest organization dedicated to training physicians in regenerative medicine. The September 12-13 event at Secrets The Vine Cancún attracted full attendance from more than 30 countries, showcasing RMTG's global reach and generating revenue through registration fees, product exhibitions, and certification programs.
Event Highlights and Revenue Generation:
The summit brought together physicians and scientists from Malaysia, Vietnam, Tajikistan, Ghana, South Africa, Japan, the United States, Spain, Italy, and multiple other nations, establishing Cancún as a global hub for regenerative medicine innovation and education. The event created multiple revenue streams through participant registrations, workshop certifications, exhibitor opportunities, and product demonstrations.
Strategic Event Components:
International Attendance: Full house participation from 30+ countries demonstrating ISSCA's global platform reach and education market leadership
Day 1 Scientific Program: Comprehensive keynote lectures from 14 international experts covering cutting-edge regenerative medicine topics, with exhibitor area featuring CELLGENIC, Eleve Health, Immunocine, Cellular Hope Institute, and MUSE Cells Innovation
Day 2 Certification Workshops: 150 certified participants across five simultaneous hands-on training sessions, generating certification fees and demonstrating ISSCA's premium education model
CELLGENIC Laboratory Showcase: Workshop participants toured the new Cancún manufacturing facility during soft opening, observing stem cell manufacturing processes and quality protocols
MedConnect Networking: Signature rooftop event at Royalton Chic Cancún fostering physician collaborations and future partnership opportunities
Revenue Streams: Event generated income through registration fees, certification programs, exhibitor booths, and product sales while establishing platform for ongoing physician relationships and training programs
"This summit proved that regenerative medicine is no longer confined by borders," said David Christensen, CEO of RMTG. "With physicians and scientists gathered from every continent, we are setting a global standard in how knowledge is shared and therapies are advanced. Between the scientific sessions, the workshops, and the networking opportunities, this event proved Mexico's growing leadership in biotechnology and medical education, while showcasing our new CELLGENIC manufacturing facility to an international audience."
Comprehensive Scientific and Training Program:
Day 1 featured keynote presentations from distinguished faculty including Prof. Mari Dezawa (Japan) on MUSE Cells and immune-modulating therapies, Dr. Rafael González (USA) on real-world evidence behind NK cells and stem cell therapies, Dr. Matt Cook (USA) on precision ultrasound-guided interventions, Dr. Alan Gaveck (USA) on engineering the immune system, Jason Pencek (USA) on next-generation cellular strategies, Prof. Dato' Sri Dr. Mike Chan (Malaysia/Europe) on bioregenerative longevity, Dr. Keith L. March (USA) on cell-free regenerative therapies, Dr. Greg Jones (USA) on peptides and hormones, Dr. Richard Silva (USA) on sports optimization, Dr. Jeff Wiegers (USA) on pain management with biologics, Dr. Vincenzo Di Donna (Italy) on organoids and ozone therapy, Prof. Roni Moya (Portugal) on regenerative biomedicine innovations, Prof. Jonathan Lakey (USA) on cellular transplantation advances, and Dr. Matthew Halpert (USA) on cancer immunology.
Premium Certification Workshops:
Day 2 delivered specialized hands-on training across five simultaneous workshops for 150 certified participants, including MUSE Cells Innovation training led by Prof. Mari Dezawa, Dr. Jeff Wiegers, and Prof. Jonathan Lakey; NK Cells and Advanced Cellular Therapies in collaboration with ImmunoSyn at ReHealth's laboratory with facility tours of the CELLGENIC manufacturing laboratory; Peptide Therapy Workshop conducted by Jason Pencek and Dr. Greg Jones; Musculoskeletal and Sports Medicine directed by Dr. Richard Silva, Dr. Wahid Burad, and Dr. Vincenzo Di Donna; and Advanced Aesthetics presented by Prof. Roni Moya and Prof. Mike Chan covering exosomes, peptides, PRP, and regenerative aesthetic therapies.
"Our goal is to close the gap between research and clinical practice, giving physicians the tools to deliver the medicine of tomorrow, today," said Benito Novas, Founder of ISSCA. "This summit is not only about science; it is about shaping a healthier future for patients. With participants from more than 30 countries, this event demonstrated the global demand for our educational platform and the value of our integrated approach combining training, certification, and access to advanced biologic products."
Market Position and Global Platform:
The summit reinforced ISSCA's position as the world's largest physician training organization in regenerative medicine, with presence in more than 20 countries and over 15 years of experience. The event demonstrated RMTG's integrated business model combining education through ISSCA, manufacturing through CELLGENIC, and product distribution through its Global Stem Cells Group subsidiary. The Cancún location showcased the strategic positioning of RMTG's new COFEPRIS-licensed manufacturing facility while providing international exposure to the Company's expanding infrastructure.
"With participants from more than 30 countries, Cancún truly became a hub of regenerative medicine," said Sarah Barroso, Managing Director of CELLGENIC. "This event proved Mexico's growing leadership in biotechnology and medical education while demonstrating the value of our new manufacturing facility to an international audience of potential customers and partners."
The successful summit aligns with RMTG's recent operational momentum, including continued sales growth in 2025 and recent expansion announcements in Puerto Rico and northern Argentina/Paraguay, adding to the Company's global affiliate network spanning 30+ countries.
https://youtu.be/ZMGZvrr59Vw?si=qAPVZlYco6m_fN6q
About RMTG:
RMTG operates through its Global Stem Cells Group subsidiary across more than 30 countries, distributing regenerative medicine solutions worldwide while specializing in physician education through its ISSCA platform. ISSCA is the world's largest organization dedicated to training physicians in regenerative medicine, with over 15 years of experience promoting education, research, and certification through international summits, academic programs, and clinical alliances. The Company's CELLGENIC brand offers a comprehensive portfolio of regenerative medicine products including exosomes, MSCs, and platelet-rich plasma kits produced under rigorous quality protocols at its COFEPRIS-licensed Cancún manufacturing facility. RMTG's integrated approach combines clinical operations, product distribution, manufacturing capabilities, and medical education to capitalize on the rapidly expanding global regenerative medicine market. To learn more, visit www.stemcellsgroup.com.
CAUTIONARY DISCLOSURE ABOUT FORWARD-LOOKING STATEMENTS
The information contained in this publication does not constitute an offer to sell or solicit an offer to buy securities of Regenerative Medical Technologies Group, Inc. (the "Company"). This publication contains forward-looking statements, which are not guarantees of future performance and may involve subjective judgment and analysis. As such, there are no assurances whatsoever that the Company will meet its expectations with respect to future revenues, event attendance, certification program enrollment, or manufacturing facility performance. The information provided herein is believed to be accurate and reliable, however the Company makes no representations or warranties, expressed or implied, as to its accuracy or completeness. There is no guarantee that future summits will achieve similar attendance levels, that certification programs will generate expected revenues, that international expansion initiatives will succeed, or that the CELLGENIC facility will achieve operational targets. The Company has no obligation to provide the recipient with additional updated information. No information in this publication should be interpreted as any indication whatsoever of the Company's future revenues, results of operations, or stock price.
Contact:
David Christensen, CEO and President
Regenerative Medical Technologies Group, Inc.
investor.relations@regenmedtechgroup.com | (800) 956-3935
SOURCE: Regenerative Medical Technology Group
View the original press release on ACCESS Newswire
FAQ
What did RMTG (OTC:RMTG) announce about the ISSCA Global Summit in Cancún on October 8, 2025?
How many participants were certified at the RMTG/ISSCA summit workshops in Cancún?
What facility did attendees tour at the RMTG summit in Cancún and what is its status?
Which revenue streams did RMTG cite from the ISSCA Regenerative Medicine Global Summit 2025?
Which types of scientific content were presented at the RMTG/ISSCA summit in Cancún?
How does RMTG position the Cancún summit relative to its global strategy (OTC:RMTG)?
